Skip to Content
Merck

Key Documents

View All Documentation

916714

A1V2PF2-NHEt

≥95%

Synonym(s):

(S)-1-((S)-2-((S)-2-Aminopropanamido)-2-cyclohexylacetyl)-N-((S)-1-(ethylamino)-3-(4-fluorophenyl)-1-oxopropan-2-yl)pyrrolidine-2-carboxamide, AVP ligand, IAP E3 ligase lead for protein degrader research, SNIPER building block

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C27H40FN5O4
Molecular Weight:
517.64
MDL number:
MFCD34166231
UNSPSC Code:
41116105
NACRES:
NA.22
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

ligand

A1V2PF2

Quality Level

100

assay

≥95%

form

powder

reaction suitability

reagent type: ligand

functional group

amine

storage temp.

2-8°C

SMILES string

N[C@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(NCC)=O)CC2=CC=C(C=C2)F)=O)=O)C3CCCCC3)=O)C

InChI

1S/C27H40FN5O4/c1-3-30-25(35)21(16-18-11-13-20(28)14-12-18)31-26(36)22-10-7-15-33(22)27(37)23(32-24(34)17(2)29)19-8-5-4-6-9-19/h11-14,17,19,21-23H,3-10,15-16,29H2,1-2H3,(H,30,35)(H,31,36)(H,32,34)/t17-,21-,22-,23-/m0/s1

InChI key

FHMJMSLAQVUJGX-ZMVGRULKSA-N

Application

A1V2PF2-NHEt is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradatio and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlight. An N-terminal variant of A1V2PF2-NHEt is also available as BocA1V2PF2 (917974).


A1V2PF2-NHEt conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining SNIPER and PROTAC® degrader libraries: Degrader Building Blocks with Inhibitor of Apoptosis Protein (IAP) In Silico-Derived Ligands

917931 A1V2PF2-NHEt-C6-NH2
916684 A1V2PF2-NHEt-C10-NH2
916935 A1V2PF2-NHEt-PEG1-NH2
917192 A1V2PF2-NHEt-PEG3-NH2

Other Notes

Technology Spotlight: Degrader Building Blocks with Inhibitor of Apoptosis Protein (IAP) In Silico-Derived Ligands

In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)

SNIPERs−Hijacking IAP activity to induce protein degradation

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
Tasuku Ishida et al.
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to
Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein